Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer.

ABSTRACT:

Background

The landscape of small cell lung cancer (SCLC) has changed since the 2019 and 2020 approvals of anti-PD-L1 atezolizumab and durvalumab for first-line (1L) treatment in combination with chemotherapy. We studied treatment patterns and real-world overall survival (rwOS) following 1L-3L therapy.

Patients and methods

A nationwide electronic health record (EHR)-derived de-identified database was used to describe treatment patterns, characteristics, and survival of patients with extensive-stage (ES)-SCLC by 1L anti-PD-L1 treatment. Patients with ES-SCLC who initiated ≥1 line of systemic therapy from 2013 to 2021, with potential follow-up through 2022, were included.

Results

Among 9952 patients with SCLC, there were 4308 patients with ES-SCLC treated during the stu

SUBMITTER: Shaw J 

PROVIDER: S-EPMC11630770 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature